Articles

Third time’s the charm

Fall brings good news from Sanofi and Regeneron on Phase III studies for two different compounds
Written byJeffrey Bouley
| 4 min read

PARIS—October and November have been good to Sanofi and Tarrytown, N.Y.-based Regeneron Pharmaceuticals Inc., as two of their partnerships yielded positive Phase III clinical trial news. First came word that the ODYSSEY MONO trial with monoclonal antibody alirocumab met its primary efficacy endpoint and that, as a monotherapy, alirocumab reduced low-density lipoprotein (LDL) cholesterol three times more than ezetimibe. Next up was the SARIL-RA-MOBILITY Phase III clinical trial of monoclonal antibody sarilumab in adult patients with active rheumatoid arthritis who were inadequate responders to methotrexate therapy, which met all three co-primary endpoints.

For Regeneron, this news adds to the momentum of its commercial success with the eye drug Eylea for wet age-related macular degeneration, and for Sanofi, it means good news after recent months brought setbacks in its oncology research and development programs.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.